Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?

The most common subtype of ovarian cancer (OC) is the high-grade serous ovarian carcinoma (HGSOC), accounting for 70%–80% of all OC deaths. Although HGSOC is a potentially immunogenic tumor, clinical studies assessing the effectiveness of inhibitors of programmed death protein and its ligand (PD-1/P...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:FRONTIERS IN ONCOLOGY 2022-09, Vol.12, p.946319-946319
Hauptverfasser: Fanale, Daniele, Corsini, Lidia Rita, Brando, Chiara, Cutaia, Sofia, Di Donna, Mariano Catello, Filorizzo, Clarissa, Lisanti, Maria Chiara, Randazzo, Ugo, Magrin, Luigi, Romano, Raffaella, Bazan Russo, Tancredi Didier, Olive, Daniel, Vieni, Salvatore, Pantuso, Gianni, Chiantera, Vito, Russo, Antonio, Bazan, Viviana, Iovanna, Juan Lucio
Format: Artikel
Sprache:eng
Schlagworte:
BTLA
butyrophilins
circulating immune checkpoints
HGSOC
Life Sciences
Oncology
PD-1
serum CA125
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The most common subtype of ovarian cancer (OC) is the high-grade serous ovarian carcinoma (HGSOC), accounting for 70%–80% of all OC deaths. Although HGSOC is a potentially immunogenic tumor, clinical studies assessing the effectiveness of inhibitors of programmed death protein and its ligand (PD-1/PD-L1) in OC patients so far showed only response rates
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.946319